Clinical and molecular epidemiology of community-onset, extended-spectrum β-lactamase-producing Escherichia coli infections in Thailand: A case-case-control study

Background Extended-spectrum β-lactamase (ESBL)-producing organisms, first identified in Germany in 1983, are now widely recognized as clinically relevant causes of infections in community. Methods Our objective was to evaluate the clinical and molecular epidemiology of community-onset, extended-spe...

Full description

Saved in:
Bibliographic Details
Published in:American journal of infection control 2007-11, Vol.35 (9), p.606-612
Main Authors: Apisarnthanarak, Anucha, MD, Kiratisin, Patarachai, MD, PhD, Saifon, Piyawan, BSc, Kitphati, Rungrueng, MD, Dejsirilert, Surang, MSc, Mundy, Linda M., MD
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Aged, 80 and over
beta-Lactam Resistance
beta-Lactamases - metabolism
Carrier State
Case-Control Studies
Cephalosporins - adverse effects
Community-Acquired Infections - epidemiology
Drug Resistance, Multiple, Bacterial
Escherichia coli - drug effects
Escherichia coli - enzymology
Escherichia coli - genetics
Escherichia coli Infections - drug therapy
Escherichia coli Infections - epidemiology
Female
Fluoroquinolones - adverse effects
Humans
Infection Control
Infectious Disease
Male
Microbial Sensitivity Tests
Middle Aged
Molecular Epidemiology
Prevalence
Risk Factors
Thailand - epidemiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Extended-spectrum β-lactamase (ESBL)-producing organisms, first identified in Germany in 1983, are now widely recognized as clinically relevant causes of infections in community. Methods Our objective was to evaluate the clinical and molecular epidemiology of community-onset, extended-spectrum β-lactamase (CO-ESBL)-producing Escherichia coli infections. We used a case-case-control study undertaken in a 450-bed, tertiary care hospital. Patients included case group (CG) I, which had confirmed CO-ESBL-producing E coli infections (n = 46). Case group (CG) II (n = 46) included patients with CO-non-ESBL-producing E coli infections. Controls (n = 138) were patients without infections. Results By multivariate analysis, diabetes (95% confidence interval [CI]: 1.9-13.2, P < .001), prior ESBL E coli colonization (
ISSN:0196-6553
1527-3296
DOI:10.1016/j.ajic.2007.05.008